空军军医大学唐都医院
Tangdu Hospital
在本站收录的 53 种疾病中,这家医院列在其中 16 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
空军军医大学唐都医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma13 篇牵头论文牵头 7 项开放试验
- 肝细胞癌Hepatocellular carcinoma16 篇牵头论文
- 胃癌Stomach cancer9 篇牵头论文牵头 1 项开放试验
- 肝母细胞瘤Hepatoblastoma1 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
- 骨肉瘤Osteosarcoma3 篇牵头论文
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder5 篇牵头论文牵头 3 项开放试验
- 重症肌无力Myasthenia gravis19 篇牵头论文牵头 3 项开放试验
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
- 大动脉炎Takayasu arteritis0 篇牵头论文
- 肝包虫病Hepatic echinococcosis0 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
- IgA 肾病IgA nephropathy0 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
- 先天性巨结肠Hirschsprung disease0 篇牵头论文
未列出的收录疾病:鼻咽癌、脊索瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.4%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 7
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
- 分期
- I/II期
- 开始
- 2026-01
- 登记号
- NCT07385001
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院西安
- 正在招募Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
- 分期
- II期
- 开始
- 2026-05
- 登记号
- NCT07452601
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院西安
- 正在招募Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
- 分期
- II期
- 开始
- 2024-10
- 登记号
- NCT06663059
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院西安
- 正在招募Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
- 分期
- II期
- 开始
- 2022-08
- 登记号
- NCT06006650
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院西安
- 即将招募Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
- 分期
- III期
- 开始
- 2026-02
- 登记号
- NCT06952621
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院西安
- 即将招募Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
- 分期
- II期
- 开始
- 2026-05
- 登记号
- NCT07618910
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院西安
- 即将招募Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2026-07
- 登记号
- NCT07678580
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院西安
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文13
- Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.
- Development and validation of a novel signature to predict the survival and affect the immune microenvironment of esophageal squamous cell carcinoma: epigenetic-related genes.
- Effect of immune infiltration intensity on the efficacy of neoadjuvant immunotherapy for esophageal cancer.
- Relaxin 2 Suppresses Tumor Growth in Esophageal Squamous Cell Carcinoma EC9706 Cells Through Modulation of the STAT Signaling Pathway.
- CircGFPT1 regulates the growth and apoptosis of esophageal squamous cell carcinoma through miR-142-5p/HAX1 axis.
- Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
- Identification of the pyroptosis-related gene signature and risk score model for esophageal squamous cell carcinoma.
- JMJD6 functions as an oncogene and is associated with poor prognosis in esophageal squamous cell carcinoma.
- Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
- WNT5A promotes the metastasis of esophageal squamous cell carcinoma by activating the HDAC7/SNAIL signaling pathway.
- Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE).
- Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
- Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
- A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
- Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
- Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
- Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
- Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
- Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
- Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC
- Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
PubMed 以外找到的论文(未计入)7
- Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis
- Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.
- Exploration on the Effects and Molecular Mechanisms of Pterostilbene on Esophageal Cancer Based on Network Pharmacology
- 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
- Effect of system analysis of reactive oxygen species on prognosis and treatment decisions for patients with esophageal squamous carcinoma.
- Elevated Serum CA724 Induced by Chemotherapy in Patients with Esophageal Squamous Cell Carcinoma
- 144P Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer (TD-NICE): A single arm, phase II study
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 4 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文16
- Diagnostic Values of Magnetic Resonance Imaging and Computed Tomography for Predicting Macrotrabecular-Massive Hepatocellular Carcinoma Subtype: A Meta-analysis.
- Exosomal Pparα derived from cancer cells induces CD8 + T cell exhaustion in hepatocellular carcinoma through the miR-27b-3p /TOX axis.
- Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma.
- Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection.
- Multiple features of cell-free mtDNA for predicting transarterial chemoembolization response in hepatocellular carcinoma.
- Role of CD5 molecular-like on hepatocellular carcinoma.
- Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
- OCTN2 enhances PGC-1α-mediated fatty acid oxidation and OXPHOS to support stemness in hepatocellular carcinoma.
- Mechanism of cancer stemness maintenance in human liver cancer.
- HCV Core protein represses DKK3 expression via epigenetic silencing and activates the Wnt/β-catenin signaling pathway during the progression of HCC.
- LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
- Down-regulation of BMAL1 by MiR-494-3p Promotes Hepatocellular Carcinoma Growth and Metastasis by Increasing GPAM-mediated Lipid Biosynthesis.
- Acyl-CoA thioesterase 9 promotes tumour growth and metastasis through reprogramming of fatty acid metabolism in hepatocellular carcinoma.
- Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation.
- Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling.
- Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function
- Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
- Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
- Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 9 篇,占 0.09%。
西安有 7 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- 分期
- 不分期
- 开始
- 2024-09
- 登记号
- NCT06128252
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院;另有 11 家列出的医院为研究中心上海、乌鲁木齐、南京、武汉、沈阳、西安、重庆
- 正在招募Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
- 分期
- 未注明
- 开始
- 2025-05
- 登记号
- NCT06979895
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学西京医院;另有 1 家列出的医院为研究中心西安
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文9
- Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma.
- SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation.
- Association of PD-L1 Expression with Clinicopathologic Characters in Gastric Cancer: A Comprehensive Meta-analysis.
- DBH-YOLO: a surgical instrument detection method based on feature separation in laparoscopic surgery.
- Development a m6A regulators characterized by the immune cell infiltration in stomach adenocarcinoma for predicting the prognosis and immunotherapy response.
- Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
- Rho GTPase-activating protein 35 suppresses gastric cancer metastasis by regulating cytoskeleton reorganization and epithelial-to-mesenchymal transition.
- A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer.
- Long non-coding RNA Down syndrome cell adhesion molecule-anti-sense 1 promotes gastric carcinoma cell proliferation and migration by regulating the miR-204/TPT1 axis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)21
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
- Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer
- New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX
- SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy
- S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis
- Evaluation of Four Reconstructions After Total Gastrectomy
- Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
- Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
- Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
- Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 5 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 12 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 27 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文3
- LINC00673 promotes osteosarcoma progression through the miR-92b-3p/DUSP1 axis.
- EYA4 reduces chemosensitivity of osteosarcoma to doxorubicin through DNA damage repair.
- Tandem mass tag (TMT) quantitative protein analysis-based proteomics and parallel reaction monitoring (PRM) validation revealed that MST4 accelerates osteosarcoma proliferation by increasing MRC2 activity.
早期论文(2016–2020 年)8
- Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma.
- LAIR-1 overexpression inhibits epithelial-mesenchymal transition in osteosarcoma via GLUT1-related energy metabolism.
- Self-seeding circulating tumor cells promote the proliferation and metastasis of human osteosarcoma by upregulating interleukin-8.
- Downregulation of the long non‑coding RNA FOXD2‑AS1 inhibits cell proliferation, migration and invasion in osteosarcoma.
- Hypoxia promotes chemotherapy resistance by down-regulating SKA1 gene expression in human osteosarcoma.
- Interleukin-6 suppression reduces tumour self-seeding by circulating tumour cells in a human osteosarcoma nude mouse model.
- [CCR7 silence by siRNA inhibits proliferation, invasion and promotes apoptosis of human MG63 osteosarcoma cells].
- [miR-365 inhibits proliferation and promotes apoptosis of SOSP9607 osteosarcoma cells].
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 2 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。
这些数字背后的记录
牵头的论文2
- Analysis of risk factors for early death of lymphocyte subsets in adult patients with secondary hemophagocytic lymphohistiocytosis.
- Development and validation of a risk stratification score for hemophagocytic syndrome in chronic active Epstein-Barr virus infection: A 10-year retrospective cohort study.
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。
西安有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
- 分期
- 不分期
- 开始
- 2025-12
- 登记号
- NCT07377305
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院西安
- 正在招募Ofatumumab in AQP4-IgG Seropositive NMOSD
- 分期
- I/II期
- 开始
- 2022-06
- 登记号
- NCT05504694
年龄 18 岁 至 未注明(登记的条件)
牵头:空军军医大学唐都医院西安
- 即将招募Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- 分期
- IV期
- 开始
- 2026-06
- 登记号
- NCT07699770
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心北京、昆明、沈阳、西安、重庆、长春
- 正在招募Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- 分期
- 早期I期
- 开始
- 2022-04
- 登记号
- NCT05145361
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、天津、太原、西安
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Long-term efficacy and safety of low-dose rituximab strategy in neuromyelitis optica spectrum disorder: a retrospective cohort study on treatment compliance and clinical outcomes.
- The levels of circulating cytokines and risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study.
- CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.
- Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.
- Emerging trends and research foci of neuromyelitis optica spectrum disorder: a 20-year bibliometric analysis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Ofatumumab in AQP4-IgG Seropositive NMOSD
- Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 19 篇,占 3.8%。
西安有 3 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 6
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
- 分期
- I期
- 开始
- 2024-07
- 登记号
- NCT06371040
年龄 18 岁 至 80 岁(登记的条件)
牵头:空军军医大学唐都医院西安
- 正在招募Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- 分期
- II期
- 开始
- 2022-07
- 登记号
- NCT05067348
年龄 18 岁 至 80 岁(登记的条件)
牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙
- 正在招募TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
- 分期
- 未注明
- 开始
- 2019-11
- 登记号
- NCT04182984
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院西安
- 正在招募Myasthenia Gravis Registry in China
- 分期
- 未注明
- 开始
- 2024-02
- 登记号
- NCT06241521
年龄未注明(登记的条件)
牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙
- 正在招募A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- 分期
- II/III期
- 开始
- 2024-07
- 登记号
- NCT06447597
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、长春、长沙
- 正在招募A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- 分期
- III期
- 开始
- 2021-07
- 登记号
- NCT04951622
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文19
- Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real-World Cohort of 77 Patients.
- Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.
- Exploring the Roles of m6A-Modified circRNAs in Myasthenia Gravis Based on Multi-Omics Analysis.
- Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study.
- Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.
- Factors associated with the disease family burden of caregivers of myasthenia gravis patients in northwestern China: A cross-sectional study.
- Nomogram for predicting the risk of postoperative myasthenic crisis in patients with thymectomy.
- ASO Author Reflections: A Possible New Etiology of Thymoma-Associated Myasthenia Gravis-Human Parvovirus B19.
- Human Parvovirus B19 May Be a Risk Factor in Myasthenia Gravis with Thymoma.
- Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
- Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis.
- Landscape analysis of m6A modification regulators related biological functions and immune characteristics in myasthenia gravis.
- Clinical characteristics and prognosis of very late-onset myasthenia gravis in China.
- Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: A propensity score analysis.
- Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis.
- Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
- Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study.
- Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.
- Detection of IgM and IgG Antibodies to Human Parvovirus B19 in Sera of Patients with Thymoma-Associated Myasthenia Gravis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
- Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
- Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
- Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis
- The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor
- Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Myasthenia Gravis Registry in China
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 3 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 4 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
其他疾病
肝包虫病
Hepatic echinococcosis2021–2025 年没有牵头肝包虫病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 2 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。
这些数字背后的记录
早期论文(2016–2020 年)1
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 12 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 10 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 8 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
其他疾病
先天性巨结肠
Hirschsprung disease2021–2025 年没有牵头先天性巨结肠的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
西安有 3 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。
联系这家医院
出示给工作人员或司机的院名卡
空军军医大学唐都医院
Tangdu Hospital
西安
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Air Force Medical University Tangdu Hospital; Tangdu Hospital of the Fourth Military Medical University; Tangdu Hospital of Air Force Military Medical University; Tangdu Hospital Fourth Military Medical University; Tangdu Hospital the Air Force Military Medical University; Tangdu Hospital of Air Force Medical University; Tangdu Hospital of the Fourth Military Medical; Tangdu hospital